Business Description
Zai Lab Ltd
NAICS : 325412
SIC : 2834
ISIN : US98887Q1040
Share Class Description:
FRA:1ZL: ADR Repr 1 ShsCompare
Compare
Traded in other countries / regions
09688.Hong KongZLAB.USAZLAB.Mexico1ZLB.Germany IPO Date
2017-09-26Description
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 53.23 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 0.44 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 63.6 | |||||
| 3-Year EBITDA Growth Rate | -3.7 | |||||
| 3-Year EPS without NRI Growth Rate | 3 | |||||
| 3-Year FCF Growth Rate | 9.8 | |||||
| 3-Year Book Growth Rate | -15 | |||||
| Future 3-5Y Total Revenue Growth Rate | 43.28 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 20.53 | |||||
| 9-Day RSI | 23.67 | |||||
| 14-Day RSI | 26.77 | |||||
| 6-1 Month Momentum % | -26.55 | |||||
| 12-1 Month Momentum % | -51.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.63 | |||||
| Quick Ratio | 4.41 | |||||
| Cash Ratio | 3.97 | |||||
| Days Inventory | 148.9 | |||||
| Days Sales Outstanding | 63.33 | |||||
| Days Payable | 279.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | 0.14 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.08 | |||||
| Operating Margin % | -140.28 | |||||
| Net Margin % | -125.46 | |||||
| FCF Margin % | -77.7 | |||||
| ROE % | -35.93 | |||||
| ROA % | -30 | |||||
| ROIC % | -334.5 | |||||
| ROC (Joel Greenblatt) % | -489.26 | |||||
| ROCE % | -38.56 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.14 | |||||
| PB Ratio | 1.73 | |||||
| Price-to-Tangible-Book | 1.77 | |||||
| EV-to-EBIT | -1.48 | |||||
| EV-to-Forward-EBIT | -6.15 | |||||
| EV-to-EBITDA | -1.52 | |||||
| EV-to-Forward-EBITDA | -6.15 | |||||
| EV-to-Revenue | 2.08 | |||||
| EV-to-Forward-Revenue | 3.25 | |||||
| EV-to-FCF | -2.68 | |||||
| Price-to-Net-Current-Asset-Value | 1.97 | |||||
| Price-to-Net-Cash | 2.44 | |||||
| Earnings Yield (Greenblatt) % | -67.57 | |||||
| FCF Yield % | -15.36 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers